(A) Longitudinal changes in variant allele frequency (VAF) of BAX mutations and other mutations in the non-CLL compartment with time in two patients treated with continuous venetoclax. Box indicates a period of azacitidine (AZA) treatment of therapy-related myeloid neoplasm in patient CLL16. Three mutations in DNMT3A (Lys382*, Gly308Alafs*8, and Trp753Arg) detected at <1.5% VAF in patient CLL3 are not shown. Two BAX mutations, Arg34* and Arg89*, were detected in CLL16 at one time point (month 56), both at VAF of 1.1%, and are therefore depicted together. (B) Schematic diagram of targeted amplicon single-cell sequencing for patient CLL16 and CLL3. Het, heterozygous.